May. 15 at 8:24 PM
$RCEL Volume was great; but the lack of power was disappointing. I believe this is significantly undervalued, and I also believe there is a real chance that this gets acquired in or before August, similar to how ScPharmaceuticals
$SCPH was last August.
My reasoning is that it's a high-margin, growing business that has limited cash. A strategic buyer can swoop in asap and try to get this for 300 million or less in the near-term, or they can wait a little longer and maybe offer north of 500 million if sequential growth continues to build each quarter. Just speculation on my part; but this looks very solid.
